Owens & Minor upgraded to Outperform from Neutral at Baird

Baird analyst Eric Coldwell upgraded Owens & Minor to Outperform from Neutral with an unchanged price target of $10. The firm believes the company could sees large cash tax benefits from the One Big Beautiful Bill and that the selloff in shares from the suspected Kaiser loss looks overblown. Owens & Minor’s core Patient Direct business remains strong, the analyst tells investors in a research note. Baird upgrades the stock following the 52% drop year-to-date